five + four) 9 (four + five) 9 (4 + five) eight (four + four)

five + four) 9 (four + five) 9 (4 + five) eight (four + four) 9 (four + five) 8 (four + 4) ISUP Grade on Biopsy 3 four five 3 five five 5 4 five five five 4 four 4 5 five five five five four 5 four Clinical T Stage T2c T1 T
five + four) 9 (4 + 5) 9 (four + five) 8 (4 + 4) 9 (4 + five) 8 (4 + 4) ISUP Grade on Biopsy 3 four five 3 5 five 5 4 five 5 5 4 4 4 5 five five 5 five four five 4 Clinical T Stage T2c T1 T2a T2c T1 T3b T2a T1 T2a T2b T2c T2a T1 T2a T2a T3b T2c T2c T2a T1 T2a TPSA: Prostate Particular Antigen; GS: Gleason Score; ISUP: International Society of Urological Pathology.3.2. PET/MRI Findings An instance of whole-body biodistribution of 68 Ga-PSMA PET and 68 Ga-DOTA-RM2 PET is reported in Figure 1. Physiological higher 68 Ga-PSMA uptake is often visualised VBIT-4 custom synthesis within the salivary and lacrimal glands, liver, spleen, small intestine, kidneys, urinary bladder and ureters (Figure 1A), while 68 Ga-DOTA-RM2 showed physiological higher uptake in the pancreatic gland and urinary bladder (Figure 1B). 68 Ga-PSMA PET detected intra-prostatic lesions in all patients, although 68 Ga-DOTA-RM2 PET identified the intraprostatic disease in 18/19 patients. In addition, in 2/22 sufferers 68 Ga-PSMA PET also detected seminal vesicles uptake. The distinct websites of intra-prostatic 68 Ga-PSMA and 68 Ga-DOTA-RM2 uptake are reported in Table 2.Diagnostics 2021, 11,7 ofTable two. TNM findings of 68 Ga-PSMA, 68 Ga-RM PET/MRI and histological validation.n. Histological Specimen T Prostate (bilateral), ECE, left SVI Prostate (bilateral), ECE NA Prostate (bilateral, correct dominant nodule) NA NA Prostate (appropriate) Prostate (bilateral, correct dominant nodule), ECE Prostate (bilateral, left dominant nodule) Prostate (suitable) Prostate (bilateral, left dominant nodule) Prostate (bilateral, left dominant nodule), ECE Prostate (bilateral, right dominant nodule), ECE, SVI NA Prostate (bilateral, appropriate dominant nodule), ECE N Left external iliac LN Tenidap Technical Information Negative NA M NA NA NA T Prostate (bilateral) Prostate (bilateral) Prostate (numerous bilateral focal uptake), SVI Prostate (right) Prostate (bilateral) Prostate (left) Prostate (proper) Prostate (correct) Prostate (left) Prostate (appropriate) Prostate (left) Prostate (left) Prostate (correct) Prostate (left) Prostate (left)68 Ga-PSMA 68 Ga-DOTA-RMMRI M Damaging Damaging Damaging T Prostate (bilateral) Prostate (bilateral) Prostate (bilateral), SVI, ECE Prostate (suitable, multiple foci) Prostate (bilateral), SVI, ECE Prostate (left), ECE Prostate (proper) Prostate (appropriate), ECE Prostate (left) Prostate (appropriate), ECE Prostate (left), ECE Prostate (left), ECE Prostate (suitable, bifocal) Prostate (left), ECE Prostate (correct) N Left external iliac Negative Left external iliac, left pararectal, Damaging left obturator, suitable obturator, external bilateral iliac Unfavorable Bilateral iliac Unfavorable Adverse Adverse Adverse Unfavorable Unfavorable Unfavorable Unfavorable M Unfavorable Negative Negative1 2N Left external iliac, left Perivescical fat Negative Left external iliac, bilateral perirectal, presacral Unfavorable Left perivescical, bilateral obturator, left external iliac Left perirectal Bilateral external iliac, appropriate common iliac Negative Unfavorable Unfavorable Unfavorable Negative Damaging Negative NegativeM Adverse Suitable iliac bone NegativeT Prostate (bilateral) Prostate (bilateral) Prostate (bilateral) Prostate (proper) Prostate (bilateral) Prostate (left) Prostate (correct) Prostate (appropriate) Prostate (left) Prostate (proper) Prostate (left) Prostate (left) Prostate (correct) Prostate (left) Prostate (proper)N Damaging Unfavorable left iliac, left perirectal hilomediastinic Left external iliac, left obturator Unfavorable Negative Negative Damaging Adverse Negative Damaging Adverse Damaging NegativeNegativeNANegativeNegativeNegative5 6 7 8 9 ten 11 12 13 1.